Bank of New York Mellon’s Takeda Pharmaceutical TAK Stock Holding History

Bank of New York Mellon’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.19M	Buy	136,772 +7,437	+6%	+$123K	﹤0.01%	2899
2026 Q1	$2.4M	Buy	129,335 +18,181	+16%	+$319K	﹤0.01%	2719
2025 Q4	$1.73M	Sell	111,154 -18,515	-14%	-$265K	﹤0.01%	2920
2025 Q3	$1.9M	Sell	129,669 -11,086	-8%	-$165K	﹤0.01%	2831
2025 Q2	$2.18M	Buy	140,755 +11,276	+9%	+$167K	﹤0.01%	2706
2025 Q1	$1.93M	Buy	129,479 +24,587	+23%	+$345K	﹤0.01%	2705
2024 Q4	$1.39M	Buy	104,892 +15,388	+17%	+$211K	﹤0.01%	2942
2024 Q3	$1.27M	Sell	89,504 -30	-0%	-$426	﹤0.01%	3001
2024 Q2	$1.16M	Sell	89,534 -21,735	-20%	-$288K	﹤0.01%	3111
2024 Q1	$1.55M	Sell	111,269 -9,027	-8%	-$131K	﹤0.01%	2911
2023 Q4	$1.72M	Sell	120,296 -16,797	-12%	-$238K	﹤0.01%	2905
2023 Q3	$2.12M	Sell	137,093 -3,841	-3%	-$59.5K	﹤0.01%	2773
2023 Q2	$2.21M	Sell	140,934 -9,186	-6%	-$151K	﹤0.01%	2777
2023 Q1	$2.47M	Buy	150,120 +9,298	+7%	+$148K	﹤0.01%	2680
2022 Q4	$2.2M	Buy	140,822 +41,104	+41%	+$574K	﹤0.01%	2812
2022 Q3	$1.29M	Buy	99,718 +28,273	+40%	+$393K	﹤0.01%	3085
2022 Q2	$1M	Buy	71,445 +7,644	+12%	+$109K	﹤0.01%	3209
2022 Q1	$914K	Buy	63,801 +13,205	+26%	+$194K	﹤0.01%	3370
2021 Q4	$689K	Sell	50,596 -10,570	-17%	-$148K	﹤0.01%	3598
2021 Q3	$1M	Sell	61,166 -5,082	-8%	-$85.3K	﹤0.01%	3392
2021 Q2	$1.11M	Buy	66,248 +1,057	+2%	+$18K	﹤0.01%	3339
2021 Q1	$1.19M	Sell	65,191 -16,982	-21%	-$306K	﹤0.01%	3240
2020 Q4	$1.5M	Sell	82,173 -3,667	-4%	-$64.3K	﹤0.01%	3014
2020 Q3	$1.53M	Sell	85,840 -24,044	-22%	-$438K	﹤0.01%	2837
2020 Q2	$1.97M	Sell	109,884 -21,311	-16%	-$383K	﹤0.01%	2691
2020 Q1	$1.99M	Buy	131,195 +21,494	+20%	+$390K	﹤0.01%	2547
2019 Q4	$2.16M	Sell	109,701 -14,692	-12%	-$281K	﹤0.01%	2783
2019 Q3	$2.14M	Sell	124,393 -43,795	-26%	-$757K	﹤0.01%	2723
2019 Q2	$2.98M	Sell	168,188 -102,636	-38%	-$1.87M	﹤0.01%	2592
2019 Q1	$5.52M	Buy	270,824 +245,980	+990%	+$4.95M	﹤0.01%	2290
2018 Q4	$418K	Buy	+24,844	New	+$419K	﹤0.01%	3575

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Bank of New York Mellon's TAK Position: Q2 2026 in Review

Bank of New York Mellon increased its Takeda Pharmaceutical (TAK) stake by 5.8% in Q2 2026, buying an estimated $123K and bringing the position to 136,772 shares worth $2.19M. The position accounts for ﹤0.01% of the portfolio, ranked #2899.

Bank of New York Mellon first reported a position in TAK in Q4 2018 and has held it in 31 quarters since. The position peaked at $5.52M in Q1 2019. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Bank of New York Mellon held 136,772 shares of Takeda Pharmaceutical worth $2.19M as of Q2 2026.
Bank of New York Mellon bought 7,437 Takeda Pharmaceutical shares in Q2 2026, an estimated $123K.
Takeda Pharmaceutical made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2899 holding.
Bank of New York Mellon first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 31 quarters since.
Bank of New York Mellon's Takeda Pharmaceutical position peaked at $5.52M in Q1 2019.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.